IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 311 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,848,816 | +10.7% | 150,988 | +0.1% | 0.02% | +14.3% |
Q2 2023 | $6,186,011 | +11.6% | 150,768 | -2.8% | 0.01% | +7.7% |
Q1 2023 | $5,544,882 | -5.4% | 155,145 | 0.0% | 0.01% | -7.1% |
Q4 2022 | $5,859,827 | -18.9% | 155,145 | -5.0% | 0.01% | -26.3% |
Q3 2022 | $7,221,000 | +18.8% | 163,255 | -0.5% | 0.02% | +26.7% |
Q2 2022 | $6,076,000 | -3.9% | 164,125 | -3.9% | 0.02% | +25.0% |
Q1 2022 | $6,324,000 | +20.0% | 170,728 | -1.5% | 0.01% | +33.3% |
Q4 2021 | $5,272,000 | -2.9% | 173,260 | +7.0% | 0.01% | -18.2% |
Q3 2021 | $5,431,000 | -17.0% | 161,938 | -1.3% | 0.01% | -8.3% |
Q2 2021 | $6,546,000 | -13.8% | 164,108 | -2.9% | 0.01% | -20.0% |
Q1 2021 | $7,597,000 | -23.5% | 168,973 | -3.8% | 0.02% | -25.0% |
Q4 2020 | $9,931,000 | +17.7% | 175,653 | -1.2% | 0.02% | +5.3% |
Q3 2020 | $8,434,000 | -19.1% | 177,743 | +0.5% | 0.02% | -26.9% |
Q2 2020 | $10,427,000 | +25.3% | 176,843 | +0.5% | 0.03% | +4.0% |
Q1 2020 | $8,321,000 | -21.5% | 176,004 | +0.3% | 0.02% | -3.8% |
Q4 2019 | $10,597,000 | -0.5% | 175,413 | -1.3% | 0.03% | -7.1% |
Q3 2019 | $10,648,000 | -7.2% | 177,738 | -0.4% | 0.03% | -6.7% |
Q2 2019 | $11,473,000 | -16.4% | 178,519 | +5.6% | 0.03% | -16.7% |
Q1 2019 | $13,726,000 | +50.2% | 169,099 | +0.0% | 0.04% | +33.3% |
Q4 2018 | $9,141,000 | +1.8% | 169,089 | -2.9% | 0.03% | +17.4% |
Q3 2018 | $8,983,000 | +22.6% | 174,166 | -1.0% | 0.02% | +15.0% |
Q2 2018 | $7,328,000 | -0.6% | 175,856 | +5.2% | 0.02% | 0.0% |
Q1 2018 | $7,370,000 | -14.0% | 167,196 | -1.9% | 0.02% | -13.0% |
Q4 2017 | $8,572,000 | -1.3% | 170,426 | -0.5% | 0.02% | -4.2% |
Q3 2017 | $8,682,000 | -0.2% | 171,246 | +0.2% | 0.02% | -4.0% |
Q2 2017 | $8,698,000 | +29.3% | 170,976 | +2.2% | 0.02% | +31.6% |
Q1 2017 | $6,728,000 | -18.0% | 167,356 | -2.4% | 0.02% | -24.0% |
Q4 2016 | $8,200,000 | +31.6% | 171,435 | +0.8% | 0.02% | +31.6% |
Q3 2016 | $6,233,000 | +52.5% | 170,111 | -3.1% | 0.02% | +46.2% |
Q2 2016 | $4,087,000 | -31.3% | 175,480 | +19.4% | 0.01% | -43.5% |
Q1 2016 | $5,952,000 | -36.9% | 146,962 | -3.5% | 0.02% | -34.3% |
Q4 2015 | $9,430,000 | – | 152,267 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |